Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases

Scientific Reports

Volumn 5, Issue , 2015, Pages 8065-

  Mao, Chen ^a   Wu, Xin Yin ^a   Yang, Zu Yao ^a   Threapleton, Diane Erin ^a   Yuan, Jin Qiu ^a   Yu, Yuan Yuan ^a   Tang, Jin Ling ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; RAS PROTEIN; TUMOR MARKER;

COLORECTAL TUMOR; FACTUAL DATABASE; GENETICS; HUMAN; LIVER TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; META ANALYSIS; METABOLISM; MUTATION; PATHOLOGY; SECONDARY;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; HUMANS; LIVER NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS;

EID: 84923013251     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08065     Document Type: Article

References (55)

1. Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360, 1408-1417, doi:10.1056/ NEJMoa0805019 (2009).
2. Bardelli, A. & Siena, S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28, 1254-1261, doi:10.1200/ jco.2009.24.6116 (2010).
3. Rajagopalan, H. et al . Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934, doi:10.1038/418934a (2002).
4. Garm Spindler, K. L. et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 20, 879-884, doi:10.1093/annonc/mdn712 (2009).
5. Douillard, J. Y. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369, 1023-34, doi: 10.1056/NEJMoa1305275 (2013).
6. Moroni, M. et al.Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6, 279-286, doi:http://dx.doi.org/10.1016/S1470-2045(05)70102-9 (2005).
7. Molinari, F. et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 100, 1087-1094, doi:10.1038/sj.bjc.6604848 (2009).
8. Zauber, P., Sabbath-Solitare, M.,Marotta, S. P. & Bishop, D. T. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol 56, 137-140, doi:10.1136/mp.56.3.137 (2003).
9. Weber, J. C. et al. Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes. Int J Cancer 120, 524-532, doi:10.1002/ijc.22343 (2007).
10. Etienne-Grimaldi, M. C. et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 14, 4830-4835, doi:10.1158/1078-0432.ccr-07-4906 (2008).
11. Albanese, I. et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 325, 784-791, doi:10.1016/ j.bbrc.2004.10.111 (2004).
12. Knijn, N. et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104, 1020-1026, doi:10.1038/bjc.2011.26 (2011).
13. Perrone, F. et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20, 84-90, doi:10.1093/annonc/mdn541 (2009).
14. Baldus, S. E. et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16, 790-799, doi:10.1158/1078-0432.ccr-09-2446 (2010).
15. Vakiani, E. et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 30, 2956-2962, doi:10.1200/jco.2011.38.2994 (2012).
16. Mariani, P. et al. Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Res 30, 4229-4235 (2010).
17. Park, J. H. et al. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 68, 1045-1055, doi:10.1007/s00280-011-1586-z (2011).
18. Tie, J. et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 17, 1122-1130, doi: 10.1158/1078-0432.CCR-10-1720 (2011).
19. Watanabe, T. et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum 54, 1170-1178, doi:10.1097/DCR.0b013e31821d37a3 (2011).
20. Bossard, C. et al. Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas. J Clin Pathol 65, 466-469, doi:10.1136/jclinpath-2011-200608 (2012).
21. Kawamoto, Y. et al. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br J Cancer 107, 340-344, doi:10.1038/bjc.2012.218 (2012).
22. Kim, M. J. et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 12, 347, doi:10.1186/1471-2407-12-347 (2012).
23. Miglio, U. et al. Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay. Pathol Res Pract 209, 233-236, doi:10.1016/j.prp.2013.02.006 (2013).
24. Mostert, B. et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 133, 130-141, doi:10.1002/ijc.27987 (2013).
25. Voutsina, A. et al. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol 26, 302-313 (2013).
26. Oliveira, C. et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 26, 158-163, doi:10.1038/sj.onc.1209758 (2007).
27. Vermaat, J. S. et al. Primary colorectal cancers and their subsequent hepatic metastases are genetically different: Implications for selection of patients for targeted treatment. Clin Cancer Res 18, 688-699, doi:10.1158/1078-0432.CCR-11-1965 (2012).
28. Shen, Y.Q., Ye, Y. B., Zheng, X.W., Li, C.&Chen, Q. K-ras mutations in colorectal cancer at different stages, Tumor 30, 134-137, doi:10.3781/j.issn.1000-7431.2010.02.010 (2010).
29. Xian, H. B., Yu, H. B. & Zhang, J. R. Comparison of the grade of concordance in terms of K-ras status between primaries and related liver metastases in colorectal cancer [article in Chinese]. Chinese Journal of Cancer Prevention and Treatment 17, 926-929 (2010).
30. Cejas, P. et al . Concordance of K-Ras status between colorectal cancer (CRC) primaries and related metastatic samples considering clinicopathological features. http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4053 [Accessed July 25, 2013].
31. Sood, A. et al. Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 28, 15s (2010).
32. Negri, F. V. et al. PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102, 162-164, doi:10.1038/sj.bjc.6605471 (2010).
33. Santini, D. et al. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice. Ann Oncol 21, 1565, doi:10.1093/annonc/mdq318 (2010).
34. Cejas, P. et al. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy. Curr Cancer Drug Targets 12, 124-131, doi:10.2174/ 156800912799095162 (2012).
35. Oudejans, J. J., Slebos, R. J., Zoetmulder, F. A., Mooi, W. J. & Rodenhuis, S. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 49, 875-879 (1991).
36. Thebo, J. S., Senagore, A. J., Reinhold, D. S. & Stapleton, S. R.Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients. Dis Colon Rectum 43, 155-159; discussion 159-162 (2000).
37. Al-Mulla, F. et al.Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol 185, 130-138, doi:10.1002/(sici)1096-9896(199806)185:2,130::aid-path85.3.0.co;2-m (1998).
38. Schimanski, C. C., Linnemann, U. & Berger, M. R. Sensitive Detection of K-ras Mutations Augments Diagnosis of Colorectal Cancer Metastases in the Liver. Cancer Res 59, 5169-5175 (1999).
39. Santini, D. et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 13, 1270-1275, doi:10.1634/theoncologist.2008-0181 (2008).
40. Melucci, E. et al. Relationship between K-Ras mutational status and EGFR expression evaluated using Allred score in primary and metastatic colorectal cancer. http://ovidsp.ovid.com/ovidweb.cgi?T5JS&PAGE5reference&D5 emed9&NEWS5N&AN570259052 [Accessed July 25, 2013].
41. Italiano, A. et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 17, 1429-1434, doi:10.1245/s10434-009-0864-z (2010).
42. Cejas, P. et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 4, e8199, doi:10.1371/journal.pone.0008199 (2009).
43. Artale, S. et al.Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26, 4217-4219, doi:10.1200/ jco.2008.18.7286 (2008).
44. Suchy, B., Zietz, C. & Rabes, H. M. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer 52, 30-33 (1992).
45. Losi, L., Benhattar, J. & Costa, J. Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer 28A, 1115-1120 (1992).
46. Finkelstein, S. D., Sayegh, R., Christensen, S. & Swalsky, P. A. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 71, 3827-3838 (1993).
47. Loupakis, F. et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27, 2622-2629, doi:10.1200/ jco.2008.20.2796 (2009).
48. Atreya, C. E. et al. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med 2, 496-506 (2013).
49. Murata, A. et al. Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer. Br J Cancer 109, 408-415. (2013).
50. Kaneko, Y., Kuramochi, H., Nakajima, G., Inoue, Y. & Yamamoto, M. Degraded DNA may induce discordance of KRAS status between primary colorectal cancer and corresponding liver metastases. Int J Clin Oncol 19, 113-120 (2014).
51. Paliogiannis, P., Cossu, A., Tanda, F., Palmieri, G. & Palomba, G. KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma. Oncol Lett 8, 1422-1426 (2014).
52. Baas, J. M., Krens, L. L., Guchelaar, H. J., Morreau, H. & Gelderblom, H. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist 16, 1239-1249, doi:10.1634/ theoncologist.2011-0024 (2011).
53. Bouchahda, M. et al. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 66, 605-609, doi:10.1007/s00280-010-1298-9 (2010).
54. Whiting, P. F. et al . QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann Intern Med 155, 529-536, doi:10.7326/0003-4819-155-8-201110180-00009 (2011).
55. Elm, E. v. et al Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335, 806-808, doi:10.1136/bmj.39335.541782.AD (2007).